Actively Recruiting
Examining tDCS Effect on Cannabis Use Disorder in Patients With Schizophrenia
Led by Centre Hospitalier Universitaire de Saint Etienne · Updated on 2026-05-06
110
Participants Needed
8
Research Sites
384 weeks
Total Duration
On this page
Sponsors
C
Centre Hospitalier Universitaire de Saint Etienne
Lead Sponsor
D
Direction Générale de l'Offre de Soins
Collaborating Sponsor
AI-Summary
What this Trial Is About
Cannabis use disorder is a frequent comorbidity of schizophrenia, associated with increased symptoms and less adherence to therapy. Validated care has limited effectiveness in this population and development of new management strategies seems necessary. Transcranial direct current stimulation (tDCS) has shown beneficial effects in both schizophrenia, substance use disorder and, in a less extent, in nicotine addiction in schizophrenic subjects. It is interesting to test if that 10 sessions of anodal stimulation of the right dorsolateral prefrontal cortex (DLPFC) and cathodal stimulation of the medial prefrontal cortex (MPFC) (by increasing control and modulating reward system), will reduce, in 110 schizophrenic subjects, cannabis consumption, and secondly craving, addiction severity, schizophrenic symptoms and improve global functioning. It is possible that these clinical effects will be associated with changes in certain cognitive functions and cerebral connectivity.
CONDITIONS
Official Title
Examining tDCS Effect on Cannabis Use Disorder in Patients With Schizophrenia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of schizophrenia according to DSM 5 criteria with stable psychotropic treatment for at least 4 weeks
- Moderate to severe cannabis use disorder according to DSM 5 with active cannabis use in the last 7 days
- Motivation to reduce or quit cannabis consumption
- Patients under ambulatory compulsory care may participate
You will not qualify if you...
- Presence of other substance use disorders except nicotine according to DSM 5
- Any other current psychiatric disorder except personality disorder according to DSM 5
- Currently hospitalized as an inpatient
- History of head injury, neurological disorder with brain impact, or severe unstable physical illness
- Pregnancy or absence of contraception
- Contraindications to tDCS or MRI such as implanted devices, uncontrolled epilepsy, or intracranial hypertension
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 8 locations
1
CH Le Vinatier Service universitaire d'addictologie de Lyon
Bron, France, 69678
Not Yet Recruiting
2
Centre Hospitalier Universitaire Service d'Addictologie et Pathologies Duelles
Clermont-Ferrand, France, 63000
Not Yet Recruiting
3
CHU de Clermont-Ferrand Service de Psychiatrie
Clermont-Ferrand, France, 63000
Not Yet Recruiting
4
Service Hospitalo-Universitaire d'Addictologie CHU de Dijon
Dijon, France, 21079
Not Yet Recruiting
5
CHU Pôle de Psychiatrie Neurologie et Rééducation
La Tronche, France, 38700
Not Yet Recruiting
6
CH Saint-Cyr-au-Mont-d'Or service de psychiatrie
Saint-Cyr-au-Mont-d'Or, France, 69450
Not Yet Recruiting
7
Centre Hospitalier Alpes Isère
Saint-Égrève, France, 38120
Not Yet Recruiting
8
CHU de Saint-Etienne
Saint-Priest-en-Jarez, France
Actively Recruiting
Research Team
A
Aurelia GAY, MD
CONTACT
B
Béatrice DEYGAS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here